CL-PTL-126: A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

February 24, 2019
https://clinicaltrials.gov/ct2/results?id=NCT03073525
Cancer - Gynecologic/ Ovarian, Cancer - Cervical
Cancer, Ovarian, Ovarian Cancer, Cervical Cancer, Uterine cancer, Advanced Gynecological Cancer, Gynecological cancer, Phase 2, Phase II, Gradalis, Atezolizumab, Biomarker
Open